Clinical Trial Update: Adjunctive Rifampin for the Treatment of Prosthetic Valve Endocarditis Due to S. Aureus [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating adjunctive rifampin for treating prosthetic valve endocarditis caused by Staphylococcus aureus is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prosthetic Valve Endocarditis
• Staphylococcus Aureus Endocarditis

Drugs mentioned

• RIFAMPIN (RIFAMPIN)

Snippet

Sponsor: Todd C. Lee MD MPH FIDSA | Conditions: Staphylococcus Aureus Endocarditis, Prosthetic Valve Endocarditis | Phase 3 | Status: RECRUITING